Inhibikase Therapeutics (NYSE:IKT) Shares Down 2.5% – What’s Next?

Shares of Inhibikase Therapeutics, Inc. (NYSE:IKT) traded down 2.5% on Monday . The company traded as low as $2.66 and last traded at $2.74. 84,282 shares were traded during trading, a decline of 32% from the average session volume of 124,099 shares. The stock had previously closed at $2.81.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. HC Wainwright cut their target price on Inhibikase Therapeutics from $15.00 to $5.00 and set a “buy” rating on the stock in a research report on Monday, October 14th. Jefferies Financial Group started coverage on shares of Inhibikase Therapeutics in a research report on Friday, November 8th. They set a “buy” rating and a $8.00 price target on the stock.

Inhibikase Therapeutics Stock Up 1.4 %

The firm has a 50-day moving average of $2.96 and a two-hundred day moving average of $2.11. The company has a market capitalization of $194.21 million, a PE ratio of -1.05 and a beta of 1.11.

About Inhibikase Therapeutics

Inhibikase Therapeutics, Inc, a clinical-stage pharmaceutical company, develops therapeutics for Parkinson’s disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson’s disease and gastrointestinal tract.